Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New emergency care supplements released in France

On March 1, 2024, the Benefit Order with the updates for 2024 was published in the Official Journal of the French Republic. Notable updates concern the terms of financing emergency care. The changes include modifications to existing supplements and the addition of new ones for emergency care services not followed by hospitalization, such as laboratory tests, imaging, specialist consultations, out-of-hours care, and specific provisions based on patient condition and age. 

Additionally, the new Annexes to the Benefit Order were added providing the lists of procedure and diagnosis codes that activate newly introduced supplements.

See the details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.